Drug intelligence / Profile preview

RV1001

Development stage: Unknown
Lead developer: Rhizen Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

RV1001 is a **novel, potent, and selective PI3Kδ inhibitor** developed by Rhizen Pharmaceuticals for the treatment of **lymphoma in dogs**. It exhibits **excellent oral bioavailability** and **anti-cancer activity** by inhibiting the PI3Kδ pathway, which is crucial for cell growth and survival in certain cancers. RV1001 has shown **single-agent efficacy** in canine Non-Hodgkin's Lymphoma (NHL), providing insights for the development of similar inhibitors for human NHL.

Targets

PIK3CD (Phosphatidylinositol 3-kinase delta)

Beyond the preview

Go deeper on RV1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RV1001.

Explore the full profile